Trevi Therapeutics, Inc. (TRVI) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Trevi Therapeutics, Inc. (TRVI) Earnings Overview
As of June 23, 2026, Trevi Therapeutics, Inc. (TRVI) reported trailing twelve-month net income of -$46M, reflecting +38.3% year-over-year growth. The company earned $-0.31 per diluted share over the past four quarters.
Looking at the long-term picture, TRVI's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2016.
Trevi Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IDYA (-$140M net income, -52.0% margin), PTCT (-$187M net income, 39.4% margin), ACAD ($376M net income, 36.5% margin), TRVI has comparable earnings metrics. Compare TRVI vs IDYA →
TRVI Earnings vs Peers
Earnings metrics vs comparable public companies
TRVI Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$43M | +10.8% | -$49M | $-0.29 | - | - |
| 2024 | -$48M | -64.8% | -$52M | $-0.47 | - | - |
| 2023 | -$29M | +0.3% | -$34M | $-0.29 | - | - |
| 2022 | -$29M | +14.1% | -$30M | $-0.45 | - | - |
| 2021 | -$34M | -3.6% | -$32M | $-1.49 | - | - |
| 2020 | -$33M | -25.8% | -$32M | $-1.81 | - | - |
| 2019 | -$26M | -26.8% | -$27M | $-1.46 | - | - |
| 2018 | -$21M | -59.8% | -$18M | $-2.29 | - | - |
| 2017 | -$13M | -16.0% | -$8M | $-1.43 | - | - |
| 2016 | -$11M | - | -$9M | $-0.69 | - | - |
Download Data
Export TRVI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TRVI — Frequently Asked Questions
Quick answers to the most common questions about buying TRVI stock.
What is TRVI earnings per share (EPS)?
TRVI trailing twelve-month (TTM) diluted EPS is $-0.31, reflecting +38.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Trevi Therapeutics, Inc.'s net income?
Trevi Therapeutics, Inc. (TRVI) trailing twelve-month net income is $-46M as of 2025. Earnings grew +38.3% year-over-year.
Is TRVI profitable?
TRVI is not currently profitable on a TTM basis, reporting a net loss of $-46M. Net margin is N/A. Investors should monitor for a return to profitability.
What is TRVI's earnings growth rate?
TRVI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are TRVI's profit margins?
Trevi Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -30.2%.
Is TRVI growing earnings?
Yes, TRVI earnings are accelerating — EPS growth of +38.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-46M. Earnings momentum is strengthening.
What was TRVI's best earnings year?
Trevi Therapeutics, Inc.'s highest annual net income on record is $-11M, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were TRVI's earnings last quarter?
TRVI's most recent reported quarter was Q1 2026. Net income was $-13M with diluted EPS of $-0.09. For a full breakdown of all quarters, see the quarterly earnings table on this page.